Vosoritide

C-type Natriuretic Peptide Analog — MUSCULO-SKELETAL SYSTEM

Key facts

Vosoritide is a drug in the C-type Natriuretic Peptide Analog class catalogued in DrugCentral. It was first approved by the EMA in 2021. DrugCentral lists 1 molecular target, including NPR2. Recorded indications include Achondroplasia.

• Drug class: C-type Natriuretic Peptide Analog.
• Molecular targets: NPR2 (1 listed in DrugCentral).
• Indications: Achondroplasia.
• ATC code: M05BX07 (Other drugs affecting bone structure and mineralization).
• Molecular formula: C176H290N56O51S3; molecular weight 4102.78 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Achondroplasia

Mechanism & targets

• Established pharmacologic class: C-type Natriuretic Peptide Analog

Molecular targets (1)

Target	Gene	Action	Activity
Atrial natriuretic peptide receptor 2	NPR2	activator	EC50 8.77

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2022-06-20	PMDA	—	BIOMARIN PHARMACEUTICAL K.K	Yes
2021-11-19	FDA	—	BIOMARIN PHARM	Yes
2021-08-26	EMA	—	BIOMARIN INTERNATIONAL LIMITED	Yes

ATC classification

ATC code	Therapeutic hierarchy
M05BX07	MUSCULO-SKELETAL SYSTEM › DRUGS FOR TREATMENT OF BONE DISEASES › DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION › Other drugs affecting bone structure and mineralization

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Foramen magnum stenosis	180.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Vosoritide is on its molecule page.

• Molecular formula: C₁₇₆H₂₉₀N₅₆O₅₁S₃
• Molecular weight: 4102.78 g/mol
• CAS number: 1480724-61-5
• InChIKey: IGYWDDBBJPSOTG-WBAGYEQSSA-N
• PubChem CID: 119058036

CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CN=CN5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@@H]6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Vosoritide used for?

DrugCentral lists the following indications for Vosoritide: Achondroplasia.

How does Vosoritide work?

Its molecular targets in DrugCentral include NPR2 (activator).

When was Vosoritide first approved?

Vosoritide was first approved by the EMA in 2021.

What drug class does Vosoritide belong to?

Vosoritide is in the C-type Natriuretic Peptide Analog class.

What is the chemical formula of Vosoritide?

Vosoritide has the molecular formula C176H290N56O51S3 and a molecular weight of 4102.78 g/mol.

Sources

• DrugCentral drug card 5480 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3707276 — compound record and bioactivity
• PubChem CID 119058036 — chemical identifiers
• DrugBank DB11928 — drug record
• FDA UNII 7SE5582Q2P — substance identity
• DailyMed: FDA labels for Vosoritide — current prescribing information (label search)
• UniProt P20594 (NPR2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.